Parental Smoking Nearly Triples Atopic Dermatitis Severity Scores in Infants

Infants with smoking parents averaged a SCORAD score (Scoring Atopic Dermatitis, a 0–103 severity index) of 33.42, nearly triple the 11.64 recorded among infants of non-smoking parents. That gap comes from a retrospective analysis of 104 patients aged 24 months or younger, all diagnosed with nonallergic atopic dermatitis, conducted by researchers at Ümraniye Training and Research Hospital in Istanbul, Türkiye. The findings appear in Advances in Dermatology and Allergology.

The comparison is striking in magnitude but, the authors concede, strictly associational. Nothing in the design proves smoke worsens dermatitis.

What did the exposure analysis show?

The team graded severity by SCORAD and stratified children by tobacco smoke exposure during the fetal period. The dose-response pattern is the study's strongest signal:

• No prenatal exposure: mean SCORAD 19.42
• One to two hours of daily exposure: 24.73
• Two to four hours: 28.49
• More than four hours daily: 38.74

A near-linear climb across exposure brackets is consistent with a biological gradient. It is also consistent with confounding, since household smoking correlates with other environmental and socioeconomic variables the researchers said they could not fully exclude.

Postnatal household smoking told a similar story. Children exposed to smoking at home after birth averaged 33.06 on SCORAD, against 19.54 for those from non-smoking households.

Which parent mattered?

Paternal smoking showed the sharpest divide: 33.03 versus 13.28 for children of non-smoking fathers. Maternal smoking during pregnancy, by contrast, showed no significant association with dermatitis severity. That asymmetry is unexplained in the reported results, and a skeptical reader should note it sits awkwardly beside the fetal-exposure findings. If prenatal smoke drives severity, one would expect maternal smoking during pregnancy to register most clearly. It did not.

The study's cohort is small, 104 patients from a single center, and the observational design cannot rule out other contributing factors. The authors state this limitation themselves.

What should clinicians take from it?

The research team emphasized family-wide smoking cessation and early prevention as the practical lever for reducing infants' exposure to tobacco smoke. For dermatologists managing infantile atopic dermatitis, the data argue for asking about household smoking as routinely as about emollient use — the paternal gap of 33.03 versus 13.28 is too large to ignore, even in an observational dataset.

The caveat remains: 104 children, one hospital, association not causation. Larger prospective cohorts with biomarkers of smoke exposure would need to replicate the dose-response curve before it justifies anything stronger than counseling. Until then, the study adds one more reason — suggestive, not definitive — to clear the air around infants with atopic dermatitis.